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During the last few years in Romania, increased numbers
of new HIV infections among ethnobotanicals intravenous
drug users (eIVDU) were observed. Although most cases
have relatively good immunological status, some patients
reclaim antiretroviral (ARV) treatment because of very low
CD4 count, severe comorbidities and/or pregnancies
despite difficulties related to their adherence.
Retrospective analysis of 32 patients, eIVDU, treated
with ARV in our hospital between 1st January 2010 and
31st January 2014.
From all 32 patients, 27 are males (84.4%). The main
reason for starting ARV treatment was represented by
severe AIDS-defining illness (71.4%) related to immunode-
pression with CD4 count below 100 cells/cmm 11 cases
(34.3%) and one pregnancy. In our study group the mean
CD4 count at baseline was of 110.1 cells/cmm (median
CD4 102.5 cells/cmm). 24 patients (75%) received at first
triple therapy including NNRTI (10 cases with nevirapine,
14 cases with efavirenz), the other 8 patients (25%)
received from the beginning regimens with protease inhi-
bitors. 7 patients from the first group were then switched
to protease inhibitors, mostly after completing tuberculo-
static treatment, while 2 patients from the second group
were switched to integrase inhibitors because of potential
drug-drug interactions involving rifampin. All patients in
our study were coinfected with HCV, 9 patients (28.9%)
had also HBV, and 15 patients (46.8%) had active tubercu-
losis. Only 15 patients were truly adherent to ARV
(43.7%); we registered 5 cases of abandon and one death.
From all 5 patients who discontinued treatment 3 were
social cases; from all 28 patients who are currently treated
20 have good family support (71.4%) and 6 (21.4%) receive
psychological counseling and methadone substitution
therapy. Mean value of CD4 count at 1 month of HAART
therapy was of 225.8 cells/cmm, probably related to ARV
treatment received correctly during admission in our
clinic, but this value decreased to 213.3 cells/cmm at 3
months, probably related to poor compliance at home.
Despite the fact that they are recently infected with HIV,
increasingly more eIVDU patients are in need of ARV
treatment, because mainly of rapid immunodepression
and comorbidities associated with AIDS. Family support
as well as psychological counseling and substitution ther-
apy with methadone are mandatory for achieving clinical
success with HAART, while lack of adherence is the prin-
cipal cause for immunological and virological failure.
Tuberculosis with both pulmonary and extrapulmonary
involvement is the principal complication associated with
AIDS, involving almost half of the eIVDU in our country.
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